JP2015534636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534636A5 JP2015534636A5 JP2015530512A JP2015530512A JP2015534636A5 JP 2015534636 A5 JP2015534636 A5 JP 2015534636A5 JP 2015530512 A JP2015530512 A JP 2015530512A JP 2015530512 A JP2015530512 A JP 2015530512A JP 2015534636 A5 JP2015534636 A5 JP 2015534636A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- control
- subject
- mdc
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 54
- 102100036845 C-C motif chemokine 22 Human genes 0.000 claims 48
- 108010083701 Chemokine CCL22 Proteins 0.000 claims 48
- 210000002966 serum Anatomy 0.000 claims 39
- 102000003812 Interleukin-15 Human genes 0.000 claims 36
- 108090000172 Interleukin-15 Proteins 0.000 claims 36
- 208000019423 liver disease Diseases 0.000 claims 28
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 27
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 24
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 24
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 23
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 21
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 21
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 16
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 16
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 15
- 239000011230 binding agent Substances 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 7
- 108010083698 Chemokine CCL26 Proteins 0.000 claims 7
- 108010082548 Chemokine CCL11 Proteins 0.000 claims 6
- 102100023688 Eotaxin Human genes 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000009870 specific binding Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 2
- 239000010836 blood and blood product Substances 0.000 claims 2
- 229940125691 blood product Drugs 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698412P | 2012-09-07 | 2012-09-07 | |
| US61/698,412 | 2012-09-07 | ||
| US201261718134P | 2012-10-24 | 2012-10-24 | |
| US61/718,134 | 2012-10-24 | ||
| PCT/IB2013/002611 WO2014037811A2 (en) | 2012-09-07 | 2013-09-06 | Methods and compositions for diagnosis of inflammatory liver disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018170224A Division JP2019012077A (ja) | 2012-09-07 | 2018-09-12 | 炎症性肝疾患の診断のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534636A JP2015534636A (ja) | 2015-12-03 |
| JP2015534636A5 true JP2015534636A5 (enExample) | 2016-10-20 |
| JP6401702B2 JP6401702B2 (ja) | 2018-10-10 |
Family
ID=50237710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530512A Expired - Fee Related JP6401702B2 (ja) | 2012-09-07 | 2013-09-06 | 炎症性肝疾患の診断のための方法および組成物 |
| JP2018170224A Pending JP2019012077A (ja) | 2012-09-07 | 2018-09-12 | 炎症性肝疾患の診断のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018170224A Pending JP2019012077A (ja) | 2012-09-07 | 2018-09-12 | 炎症性肝疾患の診断のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9535071B2 (enExample) |
| EP (1) | EP2893343B1 (enExample) |
| JP (2) | JP6401702B2 (enExample) |
| CN (1) | CN104797933A (enExample) |
| CA (1) | CA2883711A1 (enExample) |
| HK (1) | HK1212448A1 (enExample) |
| WO (1) | WO2014037811A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| US20150278726A1 (en) * | 2014-03-31 | 2015-10-01 | James Gelsin Marx | Systems and methods for workflow processing |
| EP3349785A1 (en) * | 2015-09-16 | 2018-07-25 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
| CN106153893B (zh) * | 2016-06-14 | 2018-01-16 | 浙江大学 | 唾液抗线粒体抗体m2型的酶联免疫检测试剂盒 |
| US11612888B2 (en) * | 2017-01-04 | 2023-03-28 | The Research Foundation For The State University Of New York | Biomarker detection device |
| JP6924600B2 (ja) * | 2017-04-10 | 2021-08-25 | シスメックス株式会社 | 測定方法、測定装置、プログラム、演算式の取得方法および定性判定結果の表示方法 |
| US11719694B2 (en) | 2017-10-11 | 2023-08-08 | The Governors Of The University Of Alberta | Biomarkers in autoimmune liver disease |
| CN108931517A (zh) * | 2018-07-16 | 2018-12-04 | 台州市第人民医院 | 白介素31在制备原发性胆汁性胆管炎诊断试剂或试剂盒中的应用 |
| CA3123290A1 (en) * | 2018-12-26 | 2020-07-02 | Colgate-Palmolive Company | Biomarkers of neutrophil deregulation as diagnostic for gingivitis |
| US20230237649A1 (en) * | 2020-04-15 | 2023-07-27 | Children's Hospital Medical Center | Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning |
| CN115287285B (zh) * | 2022-03-23 | 2025-03-11 | 中国人民解放军总医院第五医学中心 | 微小核糖核酸miR-126-3p及其应用 |
| WO2024216160A1 (en) * | 2023-04-14 | 2024-10-17 | Arc Research Institute | Methods and compositions for using peli2 as a biomarker |
| CN118039132A (zh) * | 2024-03-29 | 2024-05-14 | 四川大学 | 基于外观正常牙龈活检信息的大疱性疾病诊断装置及设备 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US6329159B1 (en) | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
| US20020042096A1 (en) | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US20050053938A1 (en) | 2001-11-27 | 2005-03-10 | Kohler Rainer H. | Regulation of human serine/threonine protein kinase |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| EP1520016A1 (en) | 2002-06-28 | 2005-04-06 | Bayer HealthCare AG | Human receptor tyrosine kinase mertk |
| DE60333306D1 (de) | 2002-08-30 | 2010-08-19 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen |
| US7964194B2 (en) * | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| EP1604011A4 (en) | 2003-01-21 | 2009-12-09 | Ptc Therapeutics Inc | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME |
| DE602004030586D1 (de) | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| EP1723178A4 (en) | 2004-03-12 | 2007-12-12 | Human Genome Sciences Inc | HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10 |
| US20110237664A1 (en) | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| WO2006001011A1 (en) | 2004-06-24 | 2006-01-05 | Yissum Research Development Company | Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| WO2007038749A2 (en) | 2005-09-28 | 2007-04-05 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
| US20110034396A1 (en) | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
| PL1961744T3 (pl) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
| US8158828B2 (en) | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| EP2046385B1 (en) | 2006-07-03 | 2015-03-25 | Charles David Adair | Composition for modulating the expression of cell adhesion molecules |
| CA2658394C (en) | 2006-07-12 | 2016-08-16 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| KR20090035707A (ko) | 2006-07-19 | 2009-04-10 | 더 오하이오 스테이트 유니버시티 리서치 파운데이션 | 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도 |
| EP2610244A1 (en) | 2006-08-07 | 2013-07-03 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| EA016853B1 (ru) | 2006-08-24 | 2012-08-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Замещенные ациланилиды и их применение |
| BRPI0718225A2 (pt) | 2006-10-05 | 2013-11-12 | Centocor Ortho Biotech Inc | Antagonistas de ccr2 para tratamento de fibrose |
| MX2009003583A (es) * | 2006-10-06 | 2009-04-15 | Nestec Sa | Composiciones y ensayos multiples para medir mediadores biologicos de la salud fisiologica. |
| JP2010509234A (ja) | 2006-11-02 | 2010-03-25 | シアトル ジェネティックス， インコーポレイテッド | 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2008091555A2 (en) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
| US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| NZ588554A (en) | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| SG191625A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| CN104829718A (zh) | 2008-07-08 | 2015-08-12 | 艾伯维公司 | 前列腺素e2结合蛋白及其用途 |
| SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| RU2011127198A (ru) | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | Иммуноглобулины с двойными вариабельными доменами и их применение |
| AU2010242840B2 (en) | 2009-05-01 | 2014-04-17 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| NZ596711A (en) | 2009-05-01 | 2013-11-29 | Dual variable domain immunoglobulins and uses thereof | |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| CN102612524A (zh) | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| PH12012500691A1 (en) | 2009-10-15 | 2012-11-12 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2499493A1 (en) * | 2009-11-14 | 2012-09-19 | F. Hoffmann-La Roche AG | Biomarkers for predicting rapid response to hcv treatment |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
-
2013
- 2013-09-06 HK HK16100401.5A patent/HK1212448A1/xx unknown
- 2013-09-06 JP JP2015530512A patent/JP6401702B2/ja not_active Expired - Fee Related
- 2013-09-06 US US14/423,998 patent/US9535071B2/en active Active
- 2013-09-06 CA CA2883711A patent/CA2883711A1/en not_active Abandoned
- 2013-09-06 CN CN201380053786.7A patent/CN104797933A/zh active Pending
- 2013-09-06 EP EP13835859.3A patent/EP2893343B1/en active Active
- 2013-09-06 WO PCT/IB2013/002611 patent/WO2014037811A2/en not_active Ceased
-
2016
- 2016-11-21 US US15/357,841 patent/US9952226B2/en active Active
-
2018
- 2018-03-15 US US15/922,012 patent/US10641780B2/en active Active
- 2018-09-12 JP JP2018170224A patent/JP2019012077A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534636A5 (enExample) | ||
| Parikh et al. | Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms | |
| Biswas et al. | A clonal expression biomarker associates with lung cancer mortality | |
| Chan et al. | Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment | |
| Tseng et al. | Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers | |
| Yang et al. | Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection | |
| Patel et al. | Diagnosis of liver fibrosis: present and future | |
| Zeng et al. | Applying artificial intelligence in the microbiome for gastrointestinal diseases: a review | |
| Qiao et al. | Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection | |
| CN111172279B (zh) | 外周血甲基化基因及idh1联合检测诊断肺癌模型 | |
| US12391992B2 (en) | Kit for early screening of liver cell cancer and preparation method and use thereof | |
| CN103429753A (zh) | 间皮瘤生物标记及其用途 | |
| To et al. | Hepatitis B core‐related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma | |
| Bernardi et al. | Pre-transplant ALBI grade 3 is associated with increased mortality after liver transplantation | |
| Syed et al. | Challenges in IBD research 2024: precision medicine | |
| Bhat et al. | Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients | |
| Jeon et al. | Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis | |
| Chen et al. | Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities | |
| KR20190020106A (ko) | 자가면역 질환의 차별적 진단 방법 | |
| Kim et al. | Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single‐centre cohort study | |
| Ho et al. | A new prognostic model based on albumin–bilirubin grade for hepatocellular carcinoma beyond the Milan criteria | |
| Zhang et al. | Deep learning‐based accurate diagnosis and quantitative evaluation of microvascular invasion in hepatocellular carcinoma on whole‐slide histopathology images | |
| Goossens et al. | Molecular prognostic prediction in liver cirrhosis | |
| Zhao et al. | Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis | |
| Zhu et al. | Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients |